LEADER 01808nam  2200553 a 450 
001 9910452926803321
005 20200520144314.0
010   $a1-61470-587-9
035   $a(CKB)2550000001042562
035   $a(EBL)3020374
035   $a(SSID)ssj0000860634
035   $a(PQKBManifestationID)12327566
035   $a(PQKBTitleCode)TC0000860634
035   $a(PQKBWorkID)10896299
035   $a(PQKB)10773925
035   $a(MiAaPQ)EBC3020374
035   $a(Au-PeEL)EBL3020374
035   $a(CaPaEBR)ebr10676664
035   $a(OCoLC)923663568
035   $a(EXLCZ)992550000001042562
100   $a20090730d2009      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aPioneering human myoblast genome therapy$b[electronic resource] /$fPeter K. Law ... [et al.]
210   $aNew York $cNova Biomedical Books$dc2009
215   $a1 online resource (150 p.)
225 1 $aNovinka
300   $aDescription based upon print version of record.
311   $a1-60692-817-1 
320   $aIncludes bibliographical references (p. [99]-123) and index.
327   $aIntroduction -- Myoblast transfer in DMD subjects -- Human myoblast genome therapy and the regenerative heart -- The world's first myoblast study of type II diabetic patients -- Future perspectives.
410  0$aNovinka (Series)
606   $aGene mapping
606   $aHuman gene mapping
608   $aElectronic books.
615  0$aGene mapping.
615  0$aHuman gene mapping.
676   $a572.8/633
701   $aLaw$b Peter K$0247729
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910452926803321
996   $aPioneering human myoblast genome therapy$92050038
997   $aUNINA